

## PsychRights' Medicaid Fraud Initiative Against Psychiatric Drugging of Children & Youth

James B. (Jim) Gottstein, Esq.  
Law Project for Psychiatric Rights  
Jim.Gottstein@PsychRights.org  
<http://PsychRights.org/>

1

## The Insane Psychiatric Drugging of America's Children and Youth

- Millions of Children Involved
- Very harmful with no proven benefit
- Most harmful drugs and multiple drugs (polypharmacy).
- Children and Youth in State Custody Particularly vulnerable.

1/26/2010

2

## Medicaid Fraud: Non Medically Accepted Indication

- Medicaid reimbursement prohibited for outpatient drug prescriptions except for "medically accepted indications," which means indications approved by the Food and Drug Administration (FDA) or "supported" by a citation in at least one of the following compendia:
  - American Hospital Formulary Service Drug Information,
  - United States Pharmacopeia-Drug Information (or its successor publications), or
  - DRUGDEX Information System.

1/26/2010

42 USC § 1396R-8(k)(3); 42 USC § 1396R-8(k)(6);  
42 USC § 1396R-8(g)(1)(B)(i)

3

## False Claims Act

- Civil War Era Statute to Address Rampant Fraud Against Government
- Amended in 1986 and just last year
- Allows citizens to bring suit on behalf of the government and share in recovery if any.
- Called "Relators" (for the King)

1/26/2010

31 U.S.C §3729, et seq.

4

## False Claims Act: Liability

- It is a False Claim to:
  - (A) knowingly present, or cause to be presented, a false or fraudulent claim for payment or approval
  - (B) knowingly make, use, or cause to be made or used, a false record or statement material to a false or fraudulent claim

(to the Federal Government)

31 USC §3729(a)(1)

1/26/2010

5

## False Claims Act: Knowingly Defined As:

- (i) Actual knowledge;
- (ii) Deliberate ignorance of the truth or falsity; or
- (iii) Reckless disregard of the truth or falsity

No proof of intent to defraud required

1/26/2010

31 USC §3729(b)(1)(a)

6

## False Claims Act: Pfizer/Geodon Settlement

- Multiple Drugs/Relators
- \$2.3 Billion in Criminal Fine and *Qui Tam* Recovery
- \$1.3 Billion Criminal Fine & Forfeiture
- US and States split \$1 Billion civil recovery
- *Qui Tam Relators* split \$102 million
  - Stefan Kruszewski, MD, \$29 million *relator* share for Geodon
- Promotion of Geodon for use in children for non-medically accepted indications. 7

1/26/2010

## False Claims Act: Zyprexa Settlement

- \$1.4 Billion Combined *Qui Tam* & Criminal Penalties
- \$800 million *Qui Tam* Recovery
- *Qui Tam Relators* split \$79 million
- According to NY Times, the release of the Zyprexa Papers caused investigation to “gain momentum”

1/26/2010

8

## These \$Billion Settlements Against Drug Manufacturers Not Stopping Massive, Inappropriate Psychiatric Drugging of Children & Youth

- Cost of doing business.
- Have established practice by psychiatrists and other prescribers
- The Government is continuing to pay the false claims
- Caps Liability

1/26/2010

9

## False Claims Act: Model Complaint

- Drafted for former foster youth, but anyone with non-public information (i.e., specific prescriptions) can bring.
- Cases percolating in a number of states.

1/26/2010

10

## False Claims Act: Model Complaint Defendants

- Prescribers:
  - Cause the Medicaid claims to be submitted
  - Know or should know the prescriptions are not for medically accepted indications
- Employers liable for same reason
- Pharmacies:
  - Make the false claims
  - Know or should know not for medically accepted conditions 11

1/26/2010

## False Claims Act: *US ex rel PsychRights v. Matsutani, et al.* Additional Defendants

- State Employees (personally)
  - Medicaid personnel approving claims
  - Program personnel submitting or causing false claims to be submitted
- Continuing Medical Education Provider
  - False information causing false claims

1/26/2010

12

### Examples of Drugs With No Pediatric Medically Accepted Indications (per se Medicaid Fraud)

- Symbyax (Zyprexa & Prozac together)
- Cymbalta
- Geodon
- Paxil
- Invega
- Trazadone

1/26/2010

13

### Other Pediatric non-Medically Accepted Indications (per se Medicaid Fraud)

- Virtually All Polypharmacy?
- Otherwise, see Medically Accepted Indication Chart (DRUGDEX as a practical matter)
  - For example, Oppositional Defiant Disorder is not a medically accepted indication for any neuroleptic, but seen it prescribed
- Estimate well over half are false claims.

1/26/2010

14

### Medically Accepted Indication: What Does Support Mean?

- “Whether a particular use is supported by a compendium depends on a variety of factors, including the type of drug and indication at issue, the compendium’s assessment of the drug’s efficacy in treating the indication, the content of the compendium citation, and the scope and outcome of the studies as described in the compendium.”

US Statement of Interest in *Rost v. Pfizer*,  
USDC Mass. 1:03-cv-11084-PBS

1/26/2010

15

### False Claims Act: Penalties

- \$5,500 to \$11,000 per false claim, plus treble damages.
  - Each offending prescription is a false claim

31 USC §3729(a)

1/26/2010

16

### False Claims Act: (Relator Recovery)

- If Government intervenes and takes over case, *Relator* receives 15% to 25%.
- If Government doesn’t intervene, *Relator* receives 25% to 30%.

31 USC §3730(d)

1/26/2010

17

### False Claims Act: Filed Under Seal (in Secret)

- Complaint filed under seal to allow Government time to investigate and decide whether to intervene and take over case.
  - Serve the Department of Justice with a copy of the complaint and written disclosure of substantially all material evidence and information.
  - Seal can be extended for “good cause.”
  - Average is 13 months.
  - Zyprexa: 5 years; Geodon 2 years

31 USC §3730(b)

1/26/2010

18

## False Claims Act: Prosecution of Case

- If government intervenes and takes over case, *Relator* can still participate unless found to interfere with or unduly delay the Government's prosecution of the case, or be repetitious, irrelevant, or harassing
- If government does not intervene, *Relator* gets to proceed.
- Government can settle or dismiss, but subject to court supervision with *Relator* input.

1/26/2010

31 USC §3730(c)

19

## False Claims Act: Non-Public Rule

- "No court shall have jurisdiction over an action under this section based upon the public disclosure of allegations or transactions in a criminal, civil, or administrative hearing, in a congressional, administrative, or Government Accounting Office report, hearing, audit, or investigation, or from the news media, unless the action is brought by the Attorney General or the person bringing the action is an original source of the information."

1/26/2010

31 USC §3730(e)(4)(A)

20

## False Claims Act: (First to File Rule)

- "In no event may a person bring an action . . . which is based upon allegations or transactions which are the subject of a civil suit or an administrative civil money penalty proceeding in which the Government is already a party."

1/26/2010

31 USC §3730(e)(3)


21

## False Claims Act: Miscellaneous

- Attorney required.
- Six Year Statute of Limitations

1/26/2010

22



# Medically Accepted Indications for Pediatric Use of Psychotropic Medications

## by The Law Project for Psychiatric Rights (PsychRights)

Drug	Indication (diagnosis)	FDA Approval	DRUGDEX Support for Off-Label Use	DRUGDEX Recommendation Level
------	------------------------	--------------	-----------------------------------	------------------------------

**Key:**

White Background: Medically Accepted Indication
Orange Background: Pediatric Indication cited, but not supported by DRUGDEX
Red Background: No Pediatric FDA Approval or DRUGDEX citation

<b>Abilify</b> (Aripiprazole) - Antipsychotic				
	Bipolar I Disorder - Adjunctive therapy with lithium or valproate for Acute Manic or Mixed Episodes	Yes (for 10 yrs old and up)		
	Bipolar I Disorder, monotherapy, Manic or Mixed Episodes	Yes (for 10-17 years old re acute therapy)		
	Schizophrenia	Yes (for 13-17 years old)		
<b>Adderall</b> (amphetamine/dextroamphetamine) - Central Nervous System Agent; CNS Stimulant				
	Attention Deficit Hyperactivity Disorder (ADHD)	Yes (for 3 years old and up re: [immediate-release] and 6 years old and up re: [extended-release] drug)		
	Narcolepsy	Yes (for 6 years old and up re: [immediate release] drug)		
<b>Anafranil</b> (clomipramine) - Antidepressant; Antidepressant, Tricyclic; Central Nervous System Agent				
	Depression	No		Class IIb
	Obsessive-Compulsive Disorder	Yes (for 10 years and up)		
<b>Clorazil</b> (clozapine) – Antipsychotic; Dibenzodiazepine				
	Bipolar I Disorder	No		Class IIb
	Schizophrenia, Treatment Resistant	No		cited, with no recommendation level
<b>Concerta</b> (methylphenidate) - Amphetamine Related; Central Nervous System Agent; CNS Stimulant				
	Attention Deficit Hyperactivity Disorder (ADHD)	Yes (for 6 years old to 12 years old)		
	Attention Deficit Hyperactivity Disorder (ADHD)	Yes (for 6 years old and up re ConcertaR)		
	Autistic Disorder	No		Class IIb
	Impaired Cognition - ining related to coordination/ in coordination	No		Class IIb
	Schizophrenia	No		Class IIII
	Traumatic Brain Injury	No		Class IIb
<b>Cymbalta</b> (duloxetine) - Antidepressant; Central Nervous System Agent; Neuropathic Pain Agent; Serotonin/Norepinephrine Reuptake Inhibitor				
<b>Depakote</b> (valproic acid) – Anticonvulsant; Antimigraine; Valproic Acid (class)				
	Absence Seizure, Simple and Complex and/or Complex Partial Epileptic Seizure	Yes (10 years and older)		
	Mania	No		Class IIII
	Mental Disorder - Mood Disorder	No		Class IIb
	Chorea	No		Class IIb

## Medically Accepted Indications for Pediatric Use of Psychotropic Medications by The Law Project for Psychiatric Rights (PsychRights)

Drug	Indication (diagnosis)	FDA Approval	DRUGDEX Support for Off-Label Use	DRUGDEX Recommendation Level
<b>Dexedrine</b> (dextroamphetamine) - Amphetamine (class); CNS Stimulant				
	Attention Deficit Hyperactivity Disorder (ADHD)	Yes (for 3 years to 16 years old (immediate-release) and age 6 years to 16 years old (sustained-release))		
	Narcolepsy	Yes (for 6 years old and up)		
<b>Desyrel</b> (trazodone) - Antidepressant; Triazolopyridine				
<b>Effexor</b> (venlafaxine) – Antidepressant; Antidepressant, Bicyclic; Phenethylamine (class); Serotonin/ Norepinephrine Reuptake Inhibitor				
	Attention Deficit Hyperactivity Disorder (ADHD)	No		Class IIb
	Generalized Anxiety Disorder	No		Class IIb
	Major Depressive Disorder	No		Class IIb
	Severe Major Depression with Psychotic Features	"See Drug Consult Reference: PSYCHOTIC DEPRESSION - DRUG THERAPY"		
	Social Phobia	No		Class IIb
<b>Focalin</b> (dexmethylphenidate) - Amphetamine Related; CNS Stimulant				
	Attention Deficit Hyperactivity Disorder (ADHD)	Yes (for 6 years and older)		
<b>Geodon</b> (ziprasidone) - Antipsychotic; Benzisothiazoyl				
<b>Haldol</b> (haloperidol) - Antipsychotic; Butyrophenone; Dopamine Antagonis				
	Agitation	No		Class IIb
	Hyperactive Behavior, (Short-term treatment) after failure to respond to non-antipsychotic medication and psychotherapy	Yes (for 3 years old and up)	It does not appear the injectible form (decanoate) is FDA approved for any pediatric use. DRUGDEX says safety and efficacy not established.	
	Problematic Behavior in Children (Severe), With failure to respond non-antipsychotic medication or psychotherapy	Yes (for 3 years old and up)		
	Psychotic Disorder	Yes (for 3 years old and up but ORAL formulations only)		
	Schizophrenia	Yes (for 3 years old and up but ORAL formulations only)		
<b>Invega</b> (paliperidone) - Antipsychotic; Benzisoxazole				
<b>Lamictal</b> (lamotrigine) - Anticonvulsant; Phenyltriazine				
	Bipolar Disorder, Depressed Phase	No		Class IIb
	Epilepsy, Refractory	No	Class IIa	
<b>Lexapro</b> (escitalopram)- Antianxiety, Antidepressant, Serotonin Reuptake Inhibitor				
	Major Depressive Disorder	Yes (for 12 years old and up)		
<b>Luvox</b> (fluvoxamine) - Antidepressant; Central Nervous System Agent; Serotonin Reuptake Inhibitor				
	Asperger's Disorder	No		Class IIb
	Obsessive-Compulsive Disorder	Yes (for 8 years old and up and immediate release formula only)		
	Severe Major Depression with Psychotic Features	"See Drug Consult Reference: PSYCHOTIC DEPRESSION - DRUG THERAPY"		

**Medically Accepted Indications for Pediatric Use of Psychotropic Medications**  
**by**  
**The Law Project for Psychiatric Rights (PsychRights)**

Drug	Indication (diagnosis)	FDA Approval	DRUGDEX Support for Off-Label Use	DRUGDEX Recommendation Level
<b>Mellaril</b> (thioridazine) - Antipsychotic; Phenothiazine; Piperidine	Behavioral Syndrome	No		Class III
	Schizophrenia, Refractory	Yes		
<b>Orap</b> (pimozide) - Antipsychotic; Diphenylbutylpiperidine; Dopamine Antagonist	Gilles de la Tourette's syndrome	Yes (12 years and older)		
	Anorexia Nervosa	No		Class III
<b>Paxil</b> (paroxetine) - Antidepressant; Central Nervous System Agent; Serotonin Reuptake Inhibitor				
<b>Prozac</b> (fluoxetine) - Antidepressant; Central Nervous System Agent; Serotonin Reuptake Inhibitor				
	Anxiety Disorder of Childhood	No		Class IIb
	Major Depressive Disorder	Yes (for 8 years old and up)		
	Obsessive-Compulsive Disorder	Yes (for 7 years old and up)		
	Severe Major Depression with Psychotic Features	"See Drug Consult Reference: PSYCHOTIC DEPRESSION - DRUG THERAPY"		
<b>Ritalin</b> (methylphenidate) - Amphetamine Related; Central Nervous System Agent; CNS Stimulant				
	Attention Deficit Hyperactivity Disorder (ADHD)	Yes (for 6 years to 12 years old)(extended release)		
	Attention Deficit Hyperactivity Disorder (ADHD)	Yes (for 6 years old and up)(immediate release)		
	Narcolepsy	Yes (for 6 years and up, and Ritalin(R) -SR only)		
	Schizophrenia	No		Class III
	Traumatic Brain Injury	No		Class IIb
<b>Risperdal</b> (risperidone) - Antipsychotic; Benzisoxazole				
	Autistic Disorder – Irritability	Yes (for 5 years old and up)		
	Bipolar I Disorder	Yes (for 10 years old and up)		
	Schizophrenia	Yes (for 13 years old and up, ORALLY)		
<b>Seroquel</b> (QUETIAPINE) - Antipsychotic; Dibenzothiazepine				
	Manic episodes associated with bipolar disorder	Yes, 10-17 (12/4/09)		
	Schizophrenia	Yes 13-17 (12/4/09)		
<b>Sinequan</b> (doxepin) - Antianxiety Antidepressant; Antidepressant, Tricyclic; Antiulcer Dermatological Agent				
	Alcoholism - Anxiety – Depression	Yes (for 12 years old and up)		
	Anxiety – Depression	Yes (for 12 years old and up)		
	Anxiety - Depression - Psychoneurotic personality disorder	Yes (for 12 years old and up)		

# Medically Accepted Indications for Pediatric Use of Psychotropic Medications

## by The Law Project for Psychiatric Rights (PsychRights)

Drug	Indication (diagnosis)	FDA Approval	DRUGDEX Support for Off-Label Use	DRUGDEX Recommendation Level
<b>Strattera</b> (atomoxetine) - Central Nervous System Agent; Norepinephrine Reuptake Inhibitor				
	Attention Deficit Hyperactivity Disorder (ADHD)	Yes (for 6 years old and up)		
	Attention Deficit Hyperactivity Disorder (ADHD) - Social phobia	No		Class IIb
<b>Symbyax</b> (fluoxetine hydrochloride/olanzapine) - Antidepressant; Antipsychotic				
<b>Tegretol</b> (carbamazepine) - Anticonvulsant; Antimanic; Dibenzazepine Carboxamide; Neuropathic Pain Agent				
	Epilepsy, Partial, Generalized, and Mixed types	Yes		
	Migraine; Prophylaxis			Class IIb
	Neuropathy, General			Class IIb
<b>Tofranil</b> (imipramine) - Antidepressant; Antidepressant, Tricyclic; Urinary Enuresis Agent				
	Attention Deficit Hyperactivity Disorder (ADHD), Predominantly Inattentive Type	No		Class IIb
	Depression	No		Class IIb
	Nocturnal enuresis	Yes (for 6 years old and up)		
	Separation Anxiety Disorder of Childhood	No		Class III
	Schizophrenia, Adjunct	No		Class III
<b>Trileptal</b> (oxcarbazepine) - Anticonvulsant; Dibenzazepine Carboxamide				
	Partial Seizure, monotherapy	Yes (for 4 years old and up)		
	Partial seizure; Adjunct	Yes (for 2 years old and up)		
<b>Vyvanse</b> (lisdexamfetamine) - Amphetamine (class); CNS Stimulant				
	Attention Deficit Hyperactivity Disorder (ADHD)	Yes (for 6 years old to 12 years)		
<b>Zoloft</b> (sertraline) - Antidepressant; Central Nervous System Agent; Serotonin Reuptake Inhibitor				
	Obsessive-Compulsive Disorder	Yes (6 years old and up)		
	Anorexia nervosa	No		Class III
	Generalized Anxiety Disorder	No		Class IIb
	Major Depressive Disorder	No		Class IIb
	Severe Major Depression with Psychotic Features	"See Drug Consult Reference: PSYCHOTIC DEPRESSION - DRUG THERAPY"		
<b>Zyprexa</b> (olanzapine) - Antipsychotic; Thienobenzodiazepine				
	Schizophrenia	Yes (ages 13-17), approved 12/4/09		
	manic or mixed episodes associated with bipolar I disorder	Yes (ages 13-17), approved 12/4/09		
	Bipolar 1, Disorder, Acute Mixed or Manic Episodes	Not prior to 12/4/09	Class IIa	
	Pervasive Developmental Disorder	No		Class IIb
	Severe Major Depression with Psychotic Features	"See Drug Consult Reference: PSYCHOTIC DEPRESSION - DRUG THERAPY"		

**RECOMMENDATION, EVIDENCE AND EFFICACY RATINGS**

**RESPONSE**

The Thomson Efficacy, Strength of Evidence and Strength of Recommendation definitions are outlined below:

Table 1. Strength Of Recommendation		
Class I	Recommended	The given test or treatment has been proven to be useful, and should be performed or administered.
Class IIa	Recommended, In Most Cases	The given test, or treatment is generally considered to be useful, and is indicated in most cases.
Class IIb	Recommended, In Some Cases	The given test, or treatment may be useful, and is indicated in some, but not most, cases.
Class III	Not Recommended	The given test, or treatment is not useful, and should be avoided.
Class Indeterminant	Evidence Inconclusive	

Table 2. Strength Of Evidence	
Category A	Category A evidence is based on data derived from: Meta-analyses of randomized controlled trials with homogeneity with regard to the directions and degrees of results between individual studies. Multiple, well-done randomized clinical trials involving large numbers of patients.
Category B	Category B evidence is based on data derived from: Meta-analyses of randomized controlled trials with conflicting conclusions with regard to the directions and degrees of results between individual studies. Randomized controlled trials that involved small numbers of patients or had significant methodological flaws (e.g., bias, drop-out rate, flawed analysis, etc.). Nonrandomized studies (e.g., cohort studies, case-control studies, observational studies).
Category C	Category C evidence is based on data derived from: Expert opinion or consensus, case reports or case series.
No Evidence	

Table 3. Efficacy		
Class I	Effective	Evidence and/or expert opinion suggests that a given drug treatment for a specific indication is effective
Class IIa	Evidence Favors Efficacy	Evidence and/or expert opinion is conflicting as to whether a given drug treatment for a specific indication is effective, but the weight of evidence and/or expert opinion favors efficacy.
Class IIb	Evidence is Inconclusive	Evidence and/or expert opinion is conflicting as to whether a given drug treatment for a specific indication is effective, but the weight of evidence and/or expert opinion argues against efficacy.
Class III	Ineffective	Evidence and/or expert opinion suggests that a given drug treatment for a specific indication is ineffective.

May reduce the frequency, number and severity of manic episodes in patients with schizoaffective disorders

**c) Adult:**

- 1) During the 26 to 51 months of VALPROIC ACID treatment of 15 patients with affective and SCHIZOAFFECTIVE DISORDERS, the authors observed reduction in the number, length and severity of affective episodes especially mania. In a few patients fragmentation of long and severe relapses into short and mild mania or depression occurred. The number and length of hospital admissions dropped in all patients (Puzynski & Klosiewicz, 1984).
- 2) Valproic acid, titrated to a serum level of 94 to 110 micrograms/milliliter, successfully treated AIDS-related mania in two case reports (RachBeisel & Weintraub, 1997).
- 3) Valproic acid 2000 milligrams/day was effective in the treatment of severe kleptomania and mixed mania refractory to fluoxetine in a 36-year-old female (Kmetz et al, 1997).

**4.5.A.13 Manic bipolar I disorder**

**a) Overview**

FDA Approval: Adult, no; **Pediatric, no**  
 Efficacy: Adult, Evidence favors efficacy  
 Recommendation: Adult, Class IIa  
 Strength of Evidence: Adult, Category B

See Drug Consult reference: RECOMMENDATION AND EVIDENCE RATINGS

**b) Summary:**

Valproic acid has been used for mania secondary to bipolar disorder

**c) Adult:**

- 1) Valproic acid is indicated for the treatment of the manic episodes associated with BIPOLAR DISORDER. Valproic acid is effective in the treatment of patients suffering from bipolar disorder, even in those who have failed conventional therapy (Guay, 1995)(Fawcett, 1989; Brown, 1989; Post, 1989; McElroy et al, 1989; Calabrese & Delucchi, 1989), and in bipolar disorder secondary to head injury (Pope et al, 1988).
- 2) Four out of 5 acutely manic patients responded to intravenous valproate loading in an open study (Grunze et al, 1999). Five bipolar I patients received valproate 1200 or 1800 milligrams on day 1 followed by dosage individualization based on side effects. Their mean baseline Bech-Rafaelson Mania Rating Scale score was 30.2 which improved to 8 by day 5. One patient had actually been unresponsive to oral valproate. On day 5 most were switched to oral dosing. The authors believe that with the intravenous loading a quick saturation of plasma-binding proteins occurred which could have contributed to a beneficial action.
- 3) One uncontrolled study reported improvement in 5 of 7 patients with MANIA given VALPROIC ACID (up to 1500 milligrams daily) for 6 weeks. All patients had not responded to previous therapy with LITHIUM and neuroleptics (Prasad, 1984).

**4.5.A.14 Mental disorder - Mood disorder**

**a) Overview**

FDA Approval: Adult, no; **Pediatric, no**  
 Efficacy: Adult, Evidence is inconclusive; **Pediatric, Evidence is inconclusive**  
 Recommendation: Adult, Class IIb; **Pediatric, Class IIb**  
 Strength of Evidence: Adult, Category C; Pediatric, Category C

See Drug Consult reference: RECOMMENDATION AND EVIDENCE RATINGS

**b) Summary:**

Useful in treatment of affective disorders in MENTALLY DEFICIENT PATIENTS

**c) Adult:**

- 1) Although data is limited, valproic acid appears useful in the management of AFFECTIVE DISORDERS in mentally deficient children and adults. Valproic acid was noted in studies to have advantages over carbamazepine, lithium, and antipsychotics for use in mentally retarded patients since it does not carry the same risks of tremor, incontinence, cognitive impairment, worsening of mood, and increased seizures associated with other classes of medication (Kastner et al, 1990; Sovner, 1989).
- 2) Valproic acid was useful in 5 cases of BIPOLAR DISORDER in mentally deficient adults (1 patient with Fragile X syndrome, 2 with autistic disorder, two with rapidly cycling illness) (Sovner, 1989). Valproic acid was used in doses of 1000 to 2000 milligrams daily to maintain blood levels in the usual therapeutic range of 50 to 100 mcg/mL. In 4 of these cases, therapy with antipsychotic medications was continued. Four of the 5 patients showed a significant response to valproic acid with improvements in sleep cycle, maladaptive behaviors, distractibility and assaultiveness; the other patient demonstrate only a moderate response. Antipsychotic medications were successfully tapered or discontinued in all of the patients.

**d) Pediatric:**

- 1) **Significant improvement was seen with valproic acid in 3 mentally deficient children** and adolescents with MOOD DISORDERS characterized by irritability, aggressiveness, SELF-INJURIOUS BEHAVIOR, hyperactivity and sleep disturbance; symptoms had been unresponsive to previous therapy or the patient had been unable to tolerate side effects associated with previous medications. Valproic acid 1500 to 3000 milligrams daily, at blood levels of 78 to 111 mcg/mL, produced significant improvement in all 3 patients (Kastner et al, 1990).

**4.5.A.15 Migraine; Prophylaxis**

**a) Overview**

FDA Approval: Adult, no; Pediatric, no  
 Efficacy: Adult, Effective; Pediatric, Evidence favors efficacy  
 Recommendation: Adult, Class IIb; Pediatric, Class IIb  
 Strength of Evidence: Adult, Category B; Pediatric, Category B

See Drug Consult reference: RECOMMENDATION AND EVIDENCE RATINGS

**b) Summary:**

Provides a 50% or greater reduction in migraine frequency  
 Safe and effective in adults and children  
 Effective for prophylaxis of migraine induced by a SELECTIVE SEROTONIN REUPTAKE INHIBITOR